- Can-Fite BioPharma CANF has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth.
- The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4 2021.
- The studies showed that CBD-rich T3/C15 cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3AR by inhibiting Wnt- and NF-kappa B-related regulatory pathways.
- The Wnt signaling pathway is known to be highly active in controlling the growth of liver cancer cells.
- The company has filed patent applications for cannabinoid-based therapies where the A3AR target is overexpressed, including liver cancer.
- Price Action: CANF shares are down 1.7% at $2.41 in the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
